Kodiak Sciences (KOD) Cash from Investing Activities (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Cash from Investing Activities came in at -$942000.0 in Q1 2026, down 248.89% YoY from $632686.6 in Q1 2025, and down 2090.7% on a QoQ basis from -$43000.0 in Q4 2025.
Powered by 
Analysis
Kodiak Sciences (KOD) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Cash from Investing Activities data on file, last reported at -$942000.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 248.89% year-over-year to -$942000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 million (down 37.14% YoY) and the FY2025 annual result came in at -$506000.0, up 32.98% from the prior year.
- Cash from Investing Activities slipped to -$942000.0 in Q1 2026, from -$43000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $173.4 million in Q1 2023 to a low of -$444.0 million in Q2 2022.
- A 5-year average of -$5.3 million and a median of -$166000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 8042.92% — and 2023, when it soared 1048.14%.
- Tracing KOD's Cash from Investing Activities over 5 years: stood at $67.0 million in 2022, then sank by 141.49% to -$27.8 million in 2023, then soared by 99.55% to -$124000.0 in 2024, then soared by 65.32% to -$43000.0 in 2025, then sank by 2090.7% to -$942000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$942000.0 (Q1 2026), -$43000.0 (Q4 2025), and -$60000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - | -352,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -352,000.00 |
| Mar 31, 2026 | -942,000.00 |
| Dec 31, 2025 | -43,000.00 |
| Sep 30, 2025 | -60,000.00 |
| Jun 30, 2025 | -133,000.00 |
| Mar 31, 2025 | -270,000.00 |
| Dec 31, 2024 | -124,000.00 |
| Sep 30, 2024 | -205,000.00 |
| Jun 30, 2024 | -260,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Dec 31, 2023 | -27.80 Mn |
| Sep 30, 2023 | -226,000.00 |
| Jun 30, 2023 | 103.84 Mn |
| Mar 31, 2023 | 173.41 Mn |
| Dec 31, 2022 | 67.00 Mn |
| Sep 30, 2022 | 58.73 Mn |
| Jun 30, 2022 | -443.95 Mn |
| Mar 31, 2022 | -18.29 Mn |
| Dec 31, 2021 | -10.86 Mn |
| Sep 30, 2021 | -31.71 Mn |